In recent years, the pharmaceutical industry has witnessed a surge in interest and investment in antibody-drug conjugates (ADCs), a class of targeted therapies that combine the specificity of antibodies with the cytotoxic potency of drugs. This trend is evident in the increasing heat on ADC pipeline deals, with deal sizes constantly being refreshed and setting new benchmarks.

Currently, a total of 15 ADCs have been approved for marketing globally, marking a significant milestone in the field of oncology drug development. These ADCs have demonstrated impressive efficacy in treating various types of cancers, and their market potential is enormous. In fact, the global ADCs market size was valued at US$ 5.221 billion in 2021, reflecting the strong demand for these innovative therapies.

Moreover, the annual average compound growth rate of the ADCs market has been impressive, clocking in at about 30% from 2014 to 2021. This robust growth is expected to continue in the coming years, driven by several factors including the increasing incidence of cancer, advancements in ADC technology, and the launch of new ADC products.

As the ADC market expands, so does the competition among contract development and manufacturing organizations (CDMOs) that specialize in ADC manufacturing. CDMOs play a crucial role in the ADC development process, providing expertise in formulation, manufacturing, and quality control. With the increasing demand for ADCs, CDMOs are facing increased pressure to innovate, improve efficiency, and reduce costs.

One of the key challenges facing CDMOs in the ADC space is the complexity of ADC manufacturing. ADCs are highly complex drugs that require specialized equipment, skilled personnel, and rigorous quality control measures. CDMOs need to have a deep understanding of ADC chemistry, biology, and manufacturing processes to ensure the quality and safety of the final product.

Despite these challenges, the future looks bright for CDMOs in the ADC space. With the continued growth of the ADC market and the increasing demand for ADC manufacturing services, CDMOs have the opportunity to capture a significant share of the market. By focusing on innovation, quality, and cost-effectiveness, CDMOs can position themselves as leaders in the ADC manufacturing industry and play a crucial role in advancing the field of oncology drug development.

In conclusion, as the ADC market continues to grow, CDMOs will play an increasingly critical role in enabling the development and commercialization of these innovative therapies.

Sinoway is one of those CDMO companies. We are good at developing and producing ADC linker which was made from protected amino acids and PEG derivatives. Below are some of our best-sell ADC Linkers:

For more ADC linker products or details, please feel free to contact us.